Keros Therapeutics, Inc. (KROS) Financials

KROS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 312.3 million 26.7 million
Dec. 31, 2025 338.0 million 34.9 million
Sept. 30, 2025 742.8 million 39.2 million
June 30, 2025 757.2 million 50.4 million

KROS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -3.6 million 6.2 million
Dec. 31, 2025 -27.4 million 7.3 million
Sept. 30, 2025 3.1 million 4.0 million
June 30, 2025 -30.3 million 8.5 million

KROS Net Income

No data available :(

KROS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 281.5 million 13.8 million 16.3 million
Dec. 31, 2025 287.4 million - 14.5 million
Sept. 30, 2025 693.5 million - 15.1 million
June 30, 2025 690.2 million - 18.0 million

KROS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 37.9 million
Dec. 31, 2025 37.9 million
Sept. 30, 2025 40.6 million
June 30, 2025 40.6 million

KROS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 73000 16.1 million 10.1 million -
Dec. 31, 2025 134000 17.9 million 11.7 million -
Sept. 30, 2025 132000 19.5 million 10.1 million -
June 30, 2025 720000 43.5 million 14.5 million -

KROS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 367000 403000
Dec. 31, 2025 385000 400000
Sept. 30, 2025 14.3 million 395000
June 30, 2025 18.2 million 370000

KROS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

KROS

Price: $10.50

52 week price:
9.79
22.55

Earnings Per Share: -2.53 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 412500

Market Capitalization: 336.0 million

Links: